Following the reform of the professional title system for"Breaking Four One-sided Evaluation Criteria"—focu-sing on more than just papers,titles,academic qualifications,and awards-establishing a scientific,systematic,and comprehen-sive medical performance evaluation index system has become essential for developing medical talent teams and conducting profes-sional title assessments fundamentally.This study establishes a medical performance evaluation index system tailored for clinicians in various departments of a cancer hospital who are competing for senior professional titles.This system comprises six primary in-dicators and 18 secondary indicators,with results presented in a ranked format of medical performance.Additionally,we have al-so analyzed the corr-elation between clinicians'medical performance rankings and their professional title evaluation outcomes through practical application.The results indicate that clinicians with higher performance rankings have significantly higher suc-cess rates in evaluations(P＜0.05).This index system underscores clinical practice,enhances classification-based evaluations,and supports advanced information management and precision in hospital administration,thereby providing a solid foundation for strengthening the hospital's core competitiveness.

A 53-year-old female patient with multiple metastases of colon cancer was treated with regorafenib 120 mg/d orally (21 days of medication and 7 days of withdrawal was defined as 1 cycle). On the 7th day of regorafenib treatment, the patient developed intermittent pain in the right upper abdomen and waist, which was gradually aggravated. After 20 days of waist pain, renal ultrasound and abdominal CT examination showed a right perirenal subcapsular hematoma and laboratory tests showed hemoglobin 99 g/L and normal coagulation function. Spontaneous perinephric hematoma due to regorafenib was considered. Regorafenib was discontinued, the patient was instructed to stay in bed, and hemostasis and rehydration therapy was given. After 11 days of drug withdrawal, the patient′s lumbar pain was improved and hemoglobin returned to 102 g/L. After 2 months of drug withdrawal, abdominal ultrasound showed that the right perirenal hematoma was reduced and hemoglobin returned to normal.

A 53-year-old female patient with multiple metastases of colon cancer was treated with regorafenib 120 mg/d orally (21 days of medication and 7 days of withdrawal was defined as 1 cycle). On the 7th day of regorafenib treatment, the patient developed intermittent pain in the right upper abdomen and waist, which was gradually aggravated. After 20 days of waist pain, renal ultrasound and abdominal CT examination showed a right perirenal subcapsular hematoma and laboratory tests showed hemoglobin 99 g/L and normal coagulation function. Spontaneous perinephric hematoma due to regorafenib was considered. Regorafenib was discontinued, the patient was instructed to stay in bed, and hemostasis and rehydration therapy was given. After 11 days of drug withdrawal, the patient′s lumbar pain was improved and hemoglobin returned to 102 g/L. After 2 months of drug withdrawal, abdominal ultrasound showed that the right perirenal hematoma was reduced and hemoglobin returned to normal.

A young girls took irregularly Vitamin D2 tablets (0.25 mg/tablet,each tablet contains 10 000 IU vitamin D2) purchased by her parents at a pharmacy since she was 1.5 years old.The girl took 1 tablet at a time,once to thrice daily,occasionally missing.Five months later,she developed polydipsia and polyuria.She drank more than 2 000 ml water every day,urinated once every 0.5-1 hour,and urinated more than 5 times every night.Her maximum daily urine volume could reach 3 400 ml,and her urine was transparent as clear water.Three weeks after the symptoms appeared,laboratory tests in another hospital showed that blood calcium was 4.34 mmol/L,blood phosphorus was 2.65 mmol/L,and 24-hours urine calcium was 8.0 mmol.Vitamin D poisoning was suspected and her parents were asked to stop feeding the girl vitamin D2 tablets.Rehydration,diuretics and other treatments were given.After 3 days,her blood calcium decreased to 3.60 mmol/L.After 6 days,she was transferred to Peking University First Hospital,where she continued to receive rehydration and symptomatic treatments with a low calcium and phosphorus diet.And after 8 days,the blood calcium was 2.47 mmol/L and 24-hours urine calcium was 2.7 mmol.Her symptoms of polydipsia and polyuria improved and she was discharged.Telephone follow-up 1 month after discharge,the girl's polydipsia and polyuria disappeared and her urine examination was normal.

A young girls took irregularly Vitamin D2 tablets (0.25 mg/tablet,each tablet contains 10 000 IU vitamin D2) purchased by her parents at a pharmacy since she was 1.5 years old.The girl took 1 tablet at a time,once to thrice daily,occasionally missing.Five months later,she developed polydipsia and polyuria.She drank more than 2 000 ml water every day,urinated once every 0.5-1 hour,and urinated more than 5 times every night.Her maximum daily urine volume could reach 3 400 ml,and her urine was transparent as clear water.Three weeks after the symptoms appeared,laboratory tests in another hospital showed that blood calcium was 4.34 mmol/L,blood phosphorus was 2.65 mmol/L,and 24-hours urine calcium was 8.0 mmol.Vitamin D poisoning was suspected and her parents were asked to stop feeding the girl vitamin D2 tablets.Rehydration,diuretics and other treatments were given.After 3 days,her blood calcium decreased to 3.60 mmol/L.After 6 days,she was transferred to Peking University First Hospital,where she continued to receive rehydration and symptomatic treatments with a low calcium and phosphorus diet.And after 8 days,the blood calcium was 2.47 mmol/L and 24-hours urine calcium was 2.7 mmol.Her symptoms of polydipsia and polyuria improved and she was discharged.Telephone follow-up 1 month after discharge,the girl's polydipsia and polyuria disappeared and her urine examination was normal.

Objective To study the expression changes of CD54 and CD106 in peripheral blood lymphocyte in patients with congest heart failure. Methods With FCM technique, the levels of CD54 and CD106 in lymphocyte from patients with CHF were measured , and those of patients with hypertension , patients with dilated cardiomyopathy and normal controls were measured at the same time. Cardiac function during heart failure episodes and remission stage was monitored by Color Doppler Echocardiography. Results Levels of CD54 and CD106 were significantly elevated in patients with hypertension , patients with active CHF and hypertension , patients with inactive CHF and hypertension when compared with those of normal controls. Levels of CD54 and CD106 were significantly elevated in patients of dilated cardiomyopathy , patients with active CHF and dilated cardiomyopathy , patients with inactive CHF and dilated cardiomyopathy when compared with those of normal controls. Levels of CD54 and CD106 in patients of CHF were elevated with the degree of CHF. There was significantly negative correlation between LVEF and CD54 of CHF. Conclusions CD54 and CD106 may use as the marker to monitor the progress of CHF.